PolyPhotonix

PolyPhotonix has demonstrated world-class innovation in the application of science using organic lighting to help improve the quality of life for many people.

It serves global markets from operations in the UK, Germany and US.

In just six years PolyPhotonix has grown from one employee with an idea, to manufacturing a phototherapy eye mask that independent health economists working with the NHS estimate could save on adoption of the technology in excess of £1 billion a year. PolyPhotonix have developed a treatment for one of the most common causes of blindness in the western world, Diabetic Retinopathy. The Noctura 400® treatment is provided at a fraction of current treatments costs and creates the opportunity to provide affordable treatment to the millions who are affected across the globe.